Skip to main content

Table 1 Subject characteristics

From: Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction

  Received LUM/IVA Not received LUM/IVA  
Number 10 10  
Age (range) years 26.5 (19–56) 30.6 (24–47) P = 0.9
Sex M:F 6:4 5:5  
BMI 21.5 (3.3) 21.8 (3.0) P = 0.8
FEV1% predicted 36.3 (2.8) 40.1 (6.6) P = 0.1
Range (32.4–40.1) (32.1–44.3)
FVC% predicted 66.4 (12.2) 66.5 (12.2) P = 0.8
Range (51.4–77.2) (50.8–76.5)
TLC (% predicted) 98.11 (16) 95.7 (1.4) P = 0.8
FRC (% predicted) 122 (36.3) 124 (15.1) P = 0.8
RV (% predicted) 200.4 (69.6) 198 (53) P = 0.7
DLCO (% predicted) 58 (14.6) 63 (18.2) P = 0.6
6 MWT m 532.4 (90.1) 546 (81.3) P = 0.8
CF related diabetes 5 5  
Pseudomonas 9 9  
Burkholderia Cenocepacia 1 1  
Number of exacerbations in the previous 12 months requiring IV antibiotics 3 (4.6) 2.8 (5.6) P = 0.8
Using regular nebulised DNase 10 10 NA
Using regular Azithromycin 8 9 P = 0.9
Using regular nebulised antibiotics 9 9 P = 0.8